Arteriovenous Malformations Market Report 2025

The arteriovenous malformations market size has grown strongly in recent years. It will grow from $2.88 billion in 2024 to $3.11 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to the rising prevalence of arteriovenous malformations, the increasing occurrence of neurological and brain disorders, the growing need for improved treatments for rare diseases, enhanced government support for research and development, and the expansion of the business sector.

The arteriovenous malformations market size is expected to see strong growth in the next few years. It will grow to $4.13 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The projected growth during the forecast period can be attributed to the increasing use of gene therapy, the rising demand for advanced medical technology, the growing need for quality healthcare, the increasing consumption of neurological drugs, and the expansion of the aging population. Key trends expected during this period include advancements in treatment options, innovations in medical technology, progress in microsurgical techniques, developments in catheter technology, and improvements in minimally invasive surgical procedures.

The growing demand for minimally invasive procedures is expected to drive the expansion of the arteriovenous malformations (AVMs) market. Minimally invasive procedures involve surgical or therapeutic interventions that use small incisions or catheter-based techniques to minimize trauma, reduce recovery time, and lower the risk of complications. These procedures are increasingly popular because they enable faster recovery, as smaller incisions cause less tissue damage and shorten healing times. This allows patients to return to their daily routines more quickly compared to traditional open surgeries, making them a preferred choice for both patients and healthcare providers. Arteriovenous malformations are treated using advanced techniques such as endovascular embolization, where catheters and image-guided procedures are employed to reduce abnormal blood flow without the need for open surgery. This approach leads to lower risks, quicker recovery, and improved patient outcomes. For example, in September 2023, the American Society of Plastic Surgeons reported that 25,442,640 cosmetic minimally invasive procedures were performed in 2023, reflecting a 7% increase from the 23,672,269 procedures in 2022. This growth highlights the rising preference for minimally invasive treatments and contributes to the growth of the AVMs market.

Increasing investment in biotechnology is also expected to drive the growth of the arteriovenous malformations market. Biotechnology involves the use of biological processes, organisms, or systems to develop healthcare-related products and technologies. Investment in biotechnology has surged due to breakthroughs in gene editing technologies such as CRISPR, which enable precise genetic modifications and medical innovations. Arteriovenous malformations contribute to biotechnology by improving medical imaging, gene therapy, and minimally invasive treatments, leading to the development of biotechnology-based solutions such as targeted drug delivery, biomaterials for vascular repair, and AI-assisted diagnostics. In August 2024, The BioIndustry Association (BIA) reported that the UK’s life sciences and biotechnology sector secured $2.55 billion in investment during the first two quarters of 2024, surpassing the $2.32 billion raised in 2023. This increase in biotechnology investment is helping to drive the growth of the AVMs market.

Companies in the arteriovenous malformations market are also focusing on technological advancements, such as liquid embolic system procedural sets, to enhance treatment procedures and improve patient outcomes. A liquid embolic system procedural set is a pre-assembled, sterilized kit that contains the essential components needed to deliver liquid embolic agents to treat vascular abnormalities such as AVMs. For instance, in March 2024, CERENOVUS Inc., a US-based neurovascular care company under Johnson and Johnson MedTech, introduced the TRUFILL n-BCA liquid embolic system procedural set. This new set includes two configurations and all necessary accessories for preparing and delivering the n-BCA liquid embolic system in a single sterilized package, making procedure preparation more efficient for treating cerebral AVMs.

Major players in the arteriovenous malformations market are Johnson And Johnson Services Inc., Siemens AG, Medtronic Plc, Koninklijke Philips N V, Stryker Corporation, GE Healthcare Technologies Inc, Cedars-Sinai, Penn Medicine, Terumo Corporation, Eisai Co Ltd, Cook Medical LLC, Elekta AB, Merit Medical Systems Inc., Penumbra Inc., Max Healthcare, RWJBarnabas Health, Balt LLC, Booking Health GmbH, Duke University Health System, Shape Memory Medical Inc.

North America was the largest region in the arteriovenous malformations market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in arteriovenous malformations report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the arteriovenous malformations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Arteriovenous malformations are abnormal tangles of blood vessels that form direct connections between arteries and veins, bypassing the normal capillary system. This disruption affects normal blood flow and oxygen circulation, potentially leading to complications. Early diagnosis and appropriate treatment are essential for managing symptoms and reducing the risk of severe complications.

The primary types of arteriovenous malformations include true arteriovenous malformation, occult or cryptic malformations, cavernous malformations, venous malformations, hemangiomas, dural fistulas, and others. True arteriovenous malformation is a congenital vascular anomaly characterized by a direct connection between arteries and veins, bypassing the capillary system. Diagnosis methods include physical examinations, brain scans, and other imaging techniques. Treatment options consist of endovascular embolization and neurosurgery, catering to different age groups such as adult and pediatric patients. These treatments are utilized across various end-users, including hospitals and clinics, research laboratories, and others.

The arteriovenous malformations market research report is one of a series of new reports that provides arteriovenous malformations market statistics, including arteriovenous malformations industry global market size, regional shares, competitors with a arteriovenous malformations market share, detailed arteriovenous malformations market segments, market trends and opportunities, and any further data you may need to thrive in the arteriovenous malformations industry. These arteriovenous malformations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The arteriovenous malformations market consists of revenues earned by entities by providing services such as minimally invasive embolization, post-procedure rehabilitation, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The arteriovenous malformations market also includes sales of embolization devices, neurovascular catheters, liquid embolic agents, microsurgical instruments, and imaging systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.